Defining and recognising locally advanced basal cell carcinoma
- 31 Downloads
Rarely, basal cell carcinomas (BCCs) have the potential to become extensively invasive and destructive, a phenomenon that has led to the term “locally advanced BCC” (laBCC). We identified and described the diverse settings that could be considered “locally advanced”.
The panel of experts included oncodermatologists, dermatological and maxillofacial surgeons, pathologists, radiotherapists and geriatricians. During a 1-day workshop session, an interactive flow/sequence of questions and inputs was debated.
Discussion of nine cases permitted us to approach consensus concerning what constitutes laBCC. The expert panel retained three major components for the complete assessment of laBCC cases: factors of complexity related to the tumour itself, factors related to the operability and the technical procedure, and factors related to the patient. Competing risks of death should be precisely identified. To ensure homogeneous multidisciplinary team (MDT) decisions in different clinical settings, the panel aimed to develop a practical tool based on the three components.
The grid presented is not a definitive tool, but rather, it is a method for analysing the complexity of laBCC.
Keywordsbasal cell carcinoma definition locally advanced
Unable to display preview. Download preview PDF.
- 10.Institut national du cancer. Summary Plan Plan 2014-2019. Accessed March 2, 2015 at http://www.e-cancer.fr/publications/93-plan-cancer/777-summary-plan-cancer-2014-2019-.Google Scholar
- 13.Renaud-Vilmer C, Basset-Seguin N. Carcinomes basocellulaires. Rev Praticien 2014; 64: 37–44.Google Scholar
- 17.Haute Autorité de Santé. Transparency committee. Opinion 18 December 2013, Erivedge 150 mg, gélule. Accessed March 2, 2015 at http://www.has-sante.fr/portail/jcms/c_1721873/fr/erivedgevismodegib-antineoplasique?xtmc=&xtcr=1.Google Scholar
- 19.Dréno B, Kuntsfeld R, Grob JJ, et al. Vismodegib, a hedgehog pathway inhibitor, in advanced basal cell carcinoma: an interim analysis of the STEVIE study in 500 patients. Presented at the Society for Melanoma Research 2014; November 13-16, 2014; Zurich, Switzerland.Google Scholar
- 20.Balducci L. Management of cancer in the elderly. Oncology (Williston Park) 2006; 20: 135–43, discussion 144, 146, 151-2.Google Scholar
- 24.Mortier L, Saiag Ph, Leccia MT, et al. A phase II study to assess vismodegib in the neoadjuvant treament of locally advanced basal cell carcinoma (LaBCC): the vismodegib neoadjuvant (VISMONEO) study. abstract ASCO 2014 # 307A.Google Scholar